Toll-Like Receptor 6 and Connective Tissue Growth Factor Are Significantly Upregulated in Mitomycin-C-Treated Urothelial Carcinoma Cells Under Hydrostatic Pressure Stimulation
Restricted accessResearch articleFirst published online June, 2014
Toll-Like Receptor 6 and Connective Tissue Growth Factor Are Significantly Upregulated in Mitomycin-C-Treated Urothelial Carcinoma Cells Under Hydrostatic Pressure Stimulation
Background: Urothelial carcinoma (UC) is the most common histologic subtype of bladder cancer. The administration of mitomycin C (MMC) into the bladder after transurethral resection of the bladder tumor (TURBT) is a common treatment strategy for preventing recurrence after surgery. We previously applied hydrostatic pressure combined with MMC in UC cells and found that hydrostatic pressure synergistically enhanced MMC-induced UC cell apoptosis through the Fas/FasL pathways. To understand the alteration of gene expressions in UC cells caused by hydrostatic pressure and MMC, oligonucleotide microarray was used to explore all the differentially expressed genes. Results: After bioinformatics analysis and gene annotation, Toll-like receptor 6 (TLR6) and connective tissue growth factor (CTGF) showed significant upregulation among altered genes, and their gene and protein expressions with each treatment of UC cells were validated by quantitative real-time PCR and immunoblotting. Conclusion: Under treatment with MMC and hydrostatic pressure, UC cells showed increasing apoptosis using extrinsic pathways through upregulation of TLR6 and CTGF.
Get full access to this article
View all access options for this article.
References
1.
AbreuJG, KetpuraNI, ReversadeB, De RobertisEM (2002) Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol, 4:599-604.
2.
AliprantisAO, YangRB, WeissDS, et al. (2000) The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J, 19:3325-3336.
3.
BirareN, LwaleedBA, CooperAJ (2009) Multidrug resistance in a urothelial cancer cell line after 1-hour mitomycin C exposure. J Urol, 182:2472-2476.
4.
BlaveriE, SimkoJP, KorkolaJE, et al. (2005) Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res, 11:4044-4055.
5.
BrownV, BrownRA, OzinskyA, et al. (2006) Binding specificity of Toll-like receptor cytoplasmic domains. Eur J Immunol, 36:742-753.
6.
CastilloOA, LandererE, Feria-FloresM, et al. (2012) Histological changes due to intravesical instillation of mitomycin C. Arch Esp Urol, 65:578-582; discussion 582.
7.
ChangML, YehCT, ChenJC, et al. (2008) Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis. BMC Genomics, 9:109
8.
ChenBP, LiYS, ZhaoY, et al. (2001) DNA microarray analysis of gene expression in endothelial cells in response to 24-h shear stress. Physiol Genomics, 7:55-63.
9.
ChenSK, ChungCA, ChengYC, et al. (2013) Hydrostatic pressure enhances mitomycin C-induced apoptosis in urothelial carcinoma cells. Urol Oncol, 32:26.e17-24
10.
ChoIC, KimEK, JoungJY, et al. (2012) Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea. Anticancer Res, 32:1493-1498.
11.
CrociS, LanduzziL, AstolfiA, et al. (2004) Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells. Cancer Res, 64:1730-1736.
12.
Di StasiSM, LiberatiE, DuttoL, VerriC (2008) Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. Arch Ital Urol Androl, 80:157-161.
13.
Di StasiSM, ValentiM, VerriC, et al. (2011) Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol, 12:871-879.
14.
EguchiT, KubotaS, KawataK, et al. (2008) Novel transcription-factor-like function of human matrix metalloproteinase 3 regulating the CTGF/CCN2 gene. Mol Cell Biol, 28:2391-2413.
15.
FarhatK, RiekenbergS, HeineH, et al. (2008) Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J Leukoc Biol, 83:692-701.
16.
GrotendorstGR (1997) Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev, 8:171-179.
17.
HishikawaK, OemarBS, TannerFC, et al. (1999) Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem, 274:37461-37466.
18.
HoCC (2011) Electromotive administration of mitomycin. Lancet Oncol, 12:1183.
19.
HuangCJ, ChienCC, YangSH, et al. (2008) Faecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer. J Cell Mol Med, 12:1936-1943.
20.
IntoT, KiuraK, YasudaM, et al. (2004) Stimulation of human Toll-like receptor (TLR) 2 and TLR6 with membrane lipoproteins of Mycoplasma fermentans induces apoptotic cell death after NF-kappa B activation. Cell Microbiol, 6:187
21.
JarvinenR, KaasinenE, RintalaE, GroupTF (2012) Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guerin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up. Scand J Urol Nephrol, 46:411-417.
22.
JinMS, KimSE, HeoJY, et al. (2007) Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell, 130:1071-1082.
23.
JoynerDE, JonesKB, LessnickSL, et al. (2011) Potential for modulation of the fas apoptotic pathway by epidermal growth factor in sarcomas. Sarcoma, 2011:847409
KlukasC, SchreiberF (2007) Dynamic exploration and editing of KEGG pathway diagrams. Bioinformatics, 23:344-350.
26.
LaneTF, SageEH (1994) The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J, 8:163-173.
27.
LarsonJ, YasminT, SensDA, et al. (2010) SPARC gene expression is repressed in human urothelial cells (UROtsa) exposed to or malignantly transformed by cadmium or arsenite. Toxicol Lett, 199:166-172.
28.
LinSC, LoYC, WuH (2010) Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature, 465:885-890.
29.
LoiarroM, GalloG, FantoN, et al. (2009) Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases. J Biol Chem, 284:28093-28103.
30.
MarvanovaM, LaksoM, WongG (2004) Identification of genes regulated by memantine and MK-801 in adult rat brain by cDNA microarray analysis. Neuropsychopharmacology, 29:1070-1079.
MitraAP, CoteRJ (2009) Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol, 4:251-285.
34.
MokSC, ChanWY, WongKK, et al. (1996) SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene, 12:1895-1901.
35.
NativO, WitjesJA, HendricksenK, et al. (2009) Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol, 182:1313-1317.
36.
ParkinDM, BrayF, FerlayJ, PisaniP (2005) Global cancer statistics, 2002. CA Cancer J Clin, 55:74-108.
37.
ScottMS, BartonGJ (2007) Probabilistic prediction and ranking of human protein-protein interactions. BMC Bioinformatics, 8:239.
38.
SpeersAG, LwaleedBA, FeatherstoneJM, CooperAJ (2007) Multidrug resistance in a urothelial cancer cell line after 3, 1-hour exposures to mitomycin C. J Urol, 178:2171-2175.
39.
SprickMR, WeigandMA, RieserE, et al. (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity, 12:599-609.
40.
TakedaK, AkiraS (2005) Toll-like receptors in innate immunity. Int Immunol, 17:1-14.
41.
TyritzisSI, StravodimosKG, MihalakisA, ConstantinidesCA (2009) Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours. Int Urol Nephrol, 41:865-868.
42.
van der HeijdenAG, Hulsbergen-Van de KaaCA, WitjesJA (2007) The influence of thermo-chemotherapy on bladder tumours: an immunohistochemical analysis. World J Urol, 25:303-308.
43.
WuWJ, KeHL, YangYH, et al. (2010) Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?. J Urol, 183:56-61.
44.
XieZ, ChenG, ZhangX, et al. (2013) Salivary microRNAs as promising biomarkers for detection of esophageal cancer. PLoS One, 8:e57502
45.
XuWW, HanMJ, ChenD, et al. (2013) Genome-wide search for the genes accountable for the induced resistance to HIV-1 infection in activated CD4+ T cells: apparent transcriptional signatures, co-expression networks and possible cellular processes. BMC Med Genomics, 6:15
46.
YangC, HuangC-H, CheongM-L, et al. (2009) Unambiguous molecular detections with multiple genetic approach for the complicated chromosome 22q11 deletion syndrome. BMC Med Genet, 10:16
47.
ZhangXZ, YinAH, LinDJ, et al. (2012) Analyzing gene expression profile in K562 cells exposed to sodium valproate using microarray combined with the connectivity map database. J Biomed Biotechnol, 2012:654291
48.
ZhangZ, FurgeKA, YangXJ, et al. (2010) Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. BMC Med Genomics, 3:58
